Sisi Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sisi Chen has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Feng Ren
Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, China
3 shared publications - Mei Liu
Department of Oncology, Beijing You’an Hospital, Capital Medical University, Beijing, China
3 shared publications - Ling Xu
Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, China
2 shared publications - Sujun Zheng
First Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China
2 shared publications - Yaling Cao
Beijing Institute of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing, China
2 shared publications - Yao Gao
Beijing Institute of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing, China
2 shared publications
Latest Publications
- Open Access
- 24 July 2023
- Published by JMIR Publications Inc. in JMIR Preprints
The effect of COVID-19 on patients with liver cirrhosis: A systematic review and meta-analysis of retrospective studies (Preprint)
BACKGROUND Coronavirus disease 2019 (COVID-19) is long-lasting and has an adverse effect on liver function. However, the impact of COVID-19 on the outcome of patients with liver cirrhosis has not been consistently clear. OBJECTIVE We aimed to conduct a systematic review and meta-analysis to explore whether COVID-19 negatively impacts cirrhosis patients. METHODS We conducted a systematic search of the PubMed/Medline, Embase, and Cochrane Library databases to compare cirrhosis patients with and without COVID-19. Two authors independently performed data extraction and quality evaluation using the Newcastle‒Ottawa Scale. Data pooling was conducted using random-effects or fixed-effects models based on the heterogeneity of the included studies. RESULTS A total of 13 studies were included that involved 949 patients with cirrhosis and COVID-19 and 15,196 patients with cirrhosis only. Of the 13 studies, ten were studies among hospitalized patients, and three were studies among discharged patients. COVID-19 infection increased the mortality, ICU (Intensive Care Unit) admission rate, length of hospital stay and incidence of acute-on-chronic liver failure (ACLF), Child‒Pugh C and hepatic encephalopathy among hospitalized patients with liver cirrhosis. However, COVID-19 infection did not affect the mortality rate or the incidence of Child‒Pugh C among patients with cirrhosis after discharge. CONCLUSIONS In hospitalized patients with cirrhosis, infection with COVID-19 may be a potential risk factor for adverse clinical outcomes. However, COVID-19 infection seems to have no effect on patients with cirrhosis after discharge. It is recommended that clinicians pay more attention to the prevention and treatment of COVID-19 in patients with preexisting liver cirrhosis. CLINICALTRIAL PROSPERO CRD42023429256; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=429256
- 24 July 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe effect of COVID-19 on patients with liver cirrhosis: A systematic review and meta-analysis of retrospective studies (Preprint)
BACKGROUND Coronavirus disease 2019 (COVID-19) is long-lasting and has an adverse effect on liver function. However, the impact of COVID-19 on the outcome of patients with liver cirrhosis has not been consistently clear. OBJECTIVE We aimed to conduct a systematic review and meta-analysis to explore whether COVID-19 negatively impacts cirrhosis patients. METHODS We conducted a systematic search of the PubMed/Medline, Embase, and Cochrane Library databases to compare cirrhosis patients with and without COVID-19. Two authors independently performed data extraction and quality evaluation using the Newcastle‒Ottawa Scale. Data pooling was conducted using random-effects or fixed-effects models based on the heterogeneity of the included studies. RESULTS A total of 13 studies were included that involved 949 patients with cirrhosis and COVID-19 and 15,196 patients with cirrhosis only. Of the 13 studies, ten were studies among hospitalized patients, and three were studies among discharged patients. COVID-19 infection increased the mortality, ICU (Intensive Care Unit) admission rate, length of hospital stay and incidence of acute-on-chronic liver failure (ACLF), Child‒Pugh C and hepatic encephalopathy among hospitalized patients with liver cirrhosis. However, COVID-19 infection did not affect the mortality rate or the incidence of Child‒Pugh C among patients with cirrhosis after discharge. CONCLUSIONS In hospitalized patients with cirrhosis, infection with COVID-19 may be a potential risk factor for adverse clinical outcomes. However, COVID-19 infection seems to have no effect on patients with cirrhosis after discharge. It is recommended that clinicians pay more attention to the prevention and treatment of COVID-19 in patients with preexisting liver cirrhosis. CLINICALTRIAL PROSPERO CRD42023429256; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=429256
- Open Access
- 14 June 2023
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Performance of Hepatitis Delta Virus (HDV) RNA Testing for the Diagnosis of Active HDV Infection: Systematic Review and Meta-analysis
Hepatitis delta virus (HDV) is a defective virus and causes severe liver disease. Several HDV RNA assays have been developed, however the diagnostic efficacy remains unclear.This systematic review and meta-analysis aims to evaluate the diagnostic accuracy of HDV RNA assays to aid in the diagnosis of active hepatitis D.
- 14 June 2023
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Open AccessPerformance of Hepatitis Delta Virus (HDV) RNA Testing for the Diagnosis of Active HDV Infection: Systematic Review and Meta-analysis
Hepatitis delta virus (HDV) is a defective virus and causes severe liver disease. Several HDV RNA assays have been developed, however the diagnostic efficacy remains unclear.This systematic review and meta-analysis aims to evaluate the diagnostic accuracy of HDV RNA assays to aid in the diagnosis of active hepatitis D.
- Open Access
- 29 November 2022
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 8 (11) , e37016
Underestimated Prevalence of HIV, Hepatitis B Virus (HBV), and Hepatitis D Virus (HDV) Triple Infection Globally: Systematic Review and Meta-analysis
Background: Hepatitis delta virus (HDV) is a satellite RNA virus that relies on hepatitis B virus (HBV) for transmission. HIV/HBV/HDV coinfection or triple infection is common and has a worse prognosis than monoinfection. Objective: We aimed to reveal the epidemiological characteristics of HIV/HBV/HDV triple infection in the global population. Methods: A systematic literature search in PubMed, Embase, and the Cochrane Library was performed for studies of the prevalence of HIV/HBV/HDV triple infection published from January 1, 1990, to May 31, 2021. The Der Simonian-Laird random effects model was used to calculate the pooled prevalence. Results: We included 14 studies with 11,852 participants. The pooled triple infection rate in the global population was 7.4% (877/11,852; 95% CI 0.73%-29.59%). The results of the subgroup analysis showed that the prevalence of triple infection was significantly higher in the Asian population (214/986, 21.4%; 95% CI 7.1%-35.8%), in men (212/5579, 3.8%; 95% CI 2.5%-5.2%), and in men who have sex with men (216/2734, 7.9%; 95% CI 4.3%-11.4%). In addition, compared with people living with HIV, the HIV/HBV/HDV triple infection rate was higher in people with hepatitis B. Conclusions: This meta-analysis suggests that the prevalence of HIV/HBV/HDV triple infection in the global population is underestimated, and we should focus more effort on the prevention and control of HIV/HBV/HDV triple infection. Trial Registration: PROSPERO CRD42021273949; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=273949
- 29 November 2022
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 8 (11) , e37016
Open AccessUnderestimated Prevalence of HIV, Hepatitis B Virus (HBV), and Hepatitis D Virus (HDV) Triple Infection Globally: Systematic Review and Meta-analysis
Background: Hepatitis delta virus (HDV) is a satellite RNA virus that relies on hepatitis B virus (HBV) for transmission. HIV/HBV/HDV coinfection or triple infection is common and has a worse prognosis than monoinfection. Objective: We aimed to reveal the epidemiological characteristics of HIV/HBV/HDV triple infection in the global population. Methods: A systematic literature search in PubMed, Embase, and the Cochrane Library was performed for studies of the prevalence of HIV/HBV/HDV triple infection published from January 1, 1990, to May 31, 2021. The Der Simonian-Laird random effects model was used to calculate the pooled prevalence. Results: We included 14 studies with 11,852 participants. The pooled triple infection rate in the global population was 7.4% (877/11,852; 95% CI 0.73%-29.59%). The results of the subgroup analysis showed that the prevalence of triple infection was significantly higher in the Asian population (214/986, 21.4%; 95% CI 7.1%-35.8%), in men (212/5579, 3.8%; 95% CI 2.5%-5.2%), and in men who have sex with men (216/2734, 7.9%; 95% CI 4.3%-11.4%). In addition, compared with people living with HIV, the HIV/HBV/HDV triple infection rate was higher in people with hepatitis B. Conclusions: This meta-analysis suggests that the prevalence of HIV/HBV/HDV triple infection in the global population is underestimated, and we should focus more effort on the prevention and control of HIV/HBV/HDV triple infection. Trial Registration: PROSPERO CRD42021273949; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=273949
- Open Access
- 1 November 2022
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 17 (5) , 795-805
Serum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure
Linlin Wei, Ting Wang, Sisi Chen, Yeying Liu, Xueying Huang, Sujun Zheng, Bin Xu, Feng Ren, and Mei Liu. Gut and Liver 2023;17:795-805. https://doi.org/10.5009/gnl220022
- 1 November 2022
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 17 (5) , 795-805
Open AccessSerum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure
Linlin Wei, Ting Wang, Sisi Chen, Yeying Liu, Xueying Huang, Sujun Zheng, Bin Xu, Feng Ren, and Mei Liu. Gut and Liver 2023;17:795-805. https://doi.org/10.5009/gnl220022